Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trastuzumab duocarmazine by Byondis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
BYON-4413 by Byondis for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
BYON-4413 is under clinical development by Byondis and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
BYON-4413 by Byondis for Refractory Acute Myeloid Leukemia: Likelihood of Approval
BYON-4413 is under clinical development by Byondis and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
BYON-4413 by Byondis for Myelodysplastic Syndrome: Likelihood of Approval
BYON-4413 is under clinical development by Byondis and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...
Trastuzumab duocarmazine by Byondis for Ovarian Cancer: Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Trastuzumab duocarmazine by Byondis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
SYD-3521 by Byondis for Colorectal Cancer: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
SYD-3521 by Byondis for Solid Tumor: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
SYD-3521 by Byondis for Uveal Melanoma: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Uveal Melanoma. According to GlobalData, Phase I...
SYD-3521 by Byondis for Esophageal Cancer: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I...
SYD-3521 by Byondis for Non-Small Cell Lung Cancer: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
SYD-3521 by Byondis for Pancreatic Cancer: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
Sodium thiosulfate by Byondis for Drug Toxicity: Likelihood of Approval
Sodium thiosulfate is under clinical development by Byondis and currently in Phase II for Drug Toxicity. According to GlobalData, Phase...
SYD-3521 by Byondis for Endometrial Cancer: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...
SYD-3521 by Byondis for Ovarian Cancer: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
SYD-3521 by Byondis for Cervical Cancer: Likelihood of Approval
SYD-3521 is under clinical development by Byondis and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
SYD-4228 by Byondis for Mantle Cell Lymphoma: Likelihood of Approval
SYD-4228 is under clinical development by Byondis and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase...
SYD-4228 by Byondis for Marginal Zone B-cell Lymphoma: Likelihood of Approval
SYD-4228 is under clinical development by Byondis and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData,...
SYD-4228 by Byondis for Follicular Lymphoma: Likelihood of Approval
SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I...
SYD-4228 by Byondis for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
SYD-4228 is under clinical development by Byondis and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...